explore -WSS

explore

author：comprehensive 2025-09-06 05:40:52 - browse：15797

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Histogen: Failed biotech offers rare public look inside

focus

WSS

Stroke deaths set to near 10 million globally by 2050

Analysis of telehealth claims data suggest service duplication

When women are denied an abortion, their children fare worse than peers

New England Journal of Medicine addresses racist history, slavery

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Liquid biopsy for lung cancer is launched by Delfi

leisure time

explore

hotspot

In age of alternative facts, a scholarly course on calling out crap

Bristol 'take

Psychedelics group wrestles with new pharma identity

VC firm General Catalyst wants to buy a health system

Apple is now the first public company to be valued at $3 trillion

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

New Medicare drug pricing powers could soon be upended in court

The high cost of giving birth even with insurance

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

hotspot

Was Amgen transparent enough on FDA's concern on cancer drug?

Chan Zuckerberg Biohub Chicago to focus on inflammation

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Three issues to watch in global health in 2024

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

The nurse manager staffing crisis is hurting patients

explore

focus

knowledge

explore